{"preliminary_commentary":{"by_channel":{"x_thread":2,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["vobramitamab duocarmazine"]],"indication":"metastatic castration-resistant prostate cancer","name":"TAMARACK","nct_id":"NCT05551117","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=tamarack-nct05551117. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"Tamarack","arms":[{"description":"MGC018 2.0 mg/kg every 4 weeks","label":"Part 1: MGC018 2.0 mg (Arm A)","type":"EXPERIMENTAL"},{"description":"MGC018 2.7 mg/kg every 4 weeks","label":"Part 1: MGC018 2.7 mg (Arm B)","type":"EXPERIMENTAL"},{"description":"MGC018 2.7 mg/kg every 4 weeks","label":"Part 2","type":"EXPERIMENTAL"},{"description":"Patients are administered abiraterone or enzalutamide","label":"Part 1: Control Arm","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2025-01-23","type":"ACTUAL"},"conditions":["Castration-Resistant Prostatic Cancer","Androgen-Independent Prostatic Cancer","Androgen-Insensitive Prostatic Cancer","Androgen-Resistant Prostatic Cancer","Hormone Refractory Prostatic Cancer","Anal Cancer","Anal Neoplasm","Carcinoma, Squamous Cell of Head and Neck","Head and Neck Squamous Cell Carcinoma","Laryngeal Squamous Cell Carcinoma","Oral Squamous Cell Carcinoma","Malignant Melanoma","Melanoma","Non-small Cell Lung Cancer","Non-small Cell Carcinoma","Small-cell Lung Cancer","Small Cell Carcinoma"],"enrollment":{"count":192,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"vobramitamab duocarmazine 2.0 mg (Arm A)","otherNames":["MGC018"],"type":"BIOLOGICAL"},{"name":"vobramitamab duocarmazine 2.7 mg (Arm B)","otherNames":["MGC018"],"type":"BIOLOGICAL"},{"name":"vobramitamab duocarmazine","otherNames":["MGC018"],"type":"BIOLOGICAL"},{"name":"Abiraterone","otherNames":[],"type":"DRUG"},{"name":"Enzalutamide","otherNames":[],"type":"DRUG"}],"last_update":"2026-02-09","lead_sponsor":"MacroGenics","official_title":"A Phase 2, Open-label, Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors","overall_status":"TERMINATED","phases":["PHASE2"],"primary_completion_date":{"date":"2024-07-04","type":"ACTUAL"},"primary_outcomes":[{"measure":"Part 1: Six-month Radiographic Progression Free Survival (rPFS) as Determined by the Investigator","timeFrame":"Assessed every 8 weeks for six months. Six month data reported."},{"measure":"Part 2: Objective Response Rate (ORR) Per Investigator Assessment of Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 Criteria","timeFrame":"Every 8 weeks for the first 24 weeks, then every 12 weeks. Average duration of participation, 10 months."}],"references":[],"start_date":{"date":"2023-06-13","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors","url":"https://clinicaltrials.gov/study/NCT05551117"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/tamarack-nct05551117"}